Patent SG-11201907754R-A (SG)
Title: Anti-phf-tau antibodies and uses thereof
Inventor: MERCKEN MARC
IPC: C07K16/00
Filed: 2018-03-16
Abstract: Comparisonof Recombinant PT to Purified, Hybridoma Derived PT3 . ePHF and Soluble Tau Binding 1.2 0:8 - ----ePHF - R3788 ePHF -hyb PT3 soluble - R3788 - soluble - hyb PT3 .17.4 O 0 0 LC, LX) O 0 LC, C, LV O LC/ CV CO CO CO 0, LO Cv: n mL E O 0.6 0.4 0.2 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIP0 I PCT °Ens °nolo olomonomu Imo oimIE (10) International Publication Number WO 2018/170351 Al (51) International Patent Classification: C07K 16/00 (2006.01) (21) International Application Number: PCT/US2018/022782 (22) International Filing Date: 16 March 2018 (16.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/472,214 16 March 2017 (16.03.2017) US (71) Applicant: JANSSEN BIOTECH, INC. [US/US]; 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 (US). (72) Inventors: MERCKEN, Marc; Turnhoutseweg 30, 2340 Beerse (BE). MALIA, Thomas; 825 N. 29th St., Philadel- phia, Pennsylvania 19130 (US). BORGERS, Marianne; Turnhoutseweg 30, 2340 Beerse (BE). VAN KOLEN, Kristof; Turnhoutseweg 30, 2340 Beerse (BE). (74) Agent: SHIRTZ, Joseph F. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jer- sey 08933 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: ANTI-PHF-TAU ANTIBODIES AND USES THEREOF Fla 1 1-1 11 O 1 -1 (57) : Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic © acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies C for treating or preventing conditions such as tauopathies. [Continued on next page] WO 2018/170351 Al MIDEDIMOMOIDEIREEMOMMEHOMIDINEVOIMIE Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))